Senju Pharmaceutical Co., Ltd.
千壽製藥
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| KIO-401 / mitucapistat / SJP-0008 | Phase 3 completed in Japan for CRAO; multinational Phase 3 planned for 2027 | Not disclosed | 2026-10-29 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-10-29 | Kiora Pharmaceuticals, Inc. | KIO-401 / mitucapistat / SJP-0008 | USD 3,500,000 | Not disclosed | Not disclosed | Phase 3 completed in Japan for CRAO; multinational Phase 3 planned for 2027 |